Jacob Plieth
Biotechnology
Evaluate
Australia
Biography
Jacob has 16 years’ experience of writing about healthcare and joined EP Vantage in 2012 from Edison Investment Research, where he had spent five years as an equity research analyst covering European biotech. He has also worked at Dow Jones and the Wall Street Journal, where he co-wrote a column focused on the pharmaceutical industry, and spent seven years as a reporter and editor at Scrip Pharmaceutical News. He is a biochemist by training, and has spoken about pharmaceutical and other topics on the BBC World Service and News 24, as well as contributing to publications including Investors Chronicle and Mednous. Before joining Scrip, Jacob worked as a senior editor at Pharmaprojects.
Research Interest
Business development
